Promising study results give Prescient Therapeutics a boost
Promising study results give Prescient Therapeutics a boost
General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.
About this video
Shares of Prescient Therapeutics Ltd (PTX) rose yesterday after positive news.
CEO Steven Yatomi-Clarke says the company had promising results in PTX-100's Phase 1b expansion cohort study with positive responses in patients with relapsed and refractory Peripheral T-cell lymphomas (PTCL). This is the latest in Prescient's clinical-stage oncology innovation.
Yatomi-Clarke says PTX-100 is a first-in-class compound with the ability to block an important cancer growth enzyme.